Conference Coverage
Conference Coverage
SPIRIT-H2H results confirm superiority of ixekizumab over adalimumab for PsA
ATLANTA – Biologic-naive patients with PsA responded better to ixekizumab than to adalimumab for skin and joint symptoms, and at least as well...
Conference Coverage
Expert shares tips for TNF-alpha inhibitor use in special populations
LAS VEGAS – Optimizing anti-TNF-alpha treatment starts with recognizing there is a loss of response over time, Dr. Kerdel said.
Conference Coverage
Guselkumab improves psoriatic arthritis regardless of prior TNFi use
ATLANTA – Guselkumab, an anti-IL-23p19 monoclonal antibody, showed efficacy versus placebo for active PsA in both biologic-naive and TNFi-treated...
Conference Coverage
Patients taking TNF inhibitors can safely receive Zostavax
ATLANTA – Investigators found no confirmed varicella infection cases at 6 weeks.
Conference Coverage
No infection increase seen with biologics in older psoriasis patients
MADRID – “We really think that older patients should be offered treatments at the same level of disease control as all the rest of our psoriasis...
Conference Coverage
Serlopitant improves psoriatic itch in phase 2 study
MADRID –
Conference Coverage
Psoriasis comorbidities: Biologics may help
SEATTLE – Better mental health, cardiovascular disease outcomes linked to treatment with biologics.
Conference Coverage
Secukinumab reduced joint pain of psoriatic arthritis in early data from phase 3b trial
MADRID – Secukinumab was superior to placebo for the primary endpoint of ASAS20 based on the initial 12-week data...
Conference Coverage
Novel topical psoriasis treatment targets nerve pathways
MILAN – The nonsteroidal investigative drug SNA-120 helped with psoriasis severity, burning, and pain.
Conference Coverage
Tildrakizumab shows positive effects in active psoriatic arthritis
MADRID – Already approved as a treatment for chronic plaque psoriasis, tildrakizumab (Ilumya) may also be beneficial in psoriatic arthritis,...